Soft Tissue Sarcoma Market 2018 Global Players Overview as Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Celgene Corporation and Forecasts 2023

The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR of approximately 8.2% during the forecast period 2017-2023. Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues.

Generally occurring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma and others.

Intended Audience

Soft Tissue Sarcoma Drug Suppliers
Soft Tissue Sarcoma Drug Manufacturers
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities
Segmentation

The Soft Tissue Sarcoma is segmented on the basis of treatment, disease type, distribution channel, and end-users.

On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcatergorized into internal radiation therapy and external radiation therapy.

On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma

On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.

On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Request a Free Sample of Soft Tissue Sarcoma Market Report @ https://www.marketresearchfuture.com/sample_request/5304 .

Key Players

Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Regional Analysis

The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.

Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.

The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.

Browse Full Report @ https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com .

This release was published on openPR.